Putative therapeutic agents for the learning and memory deficits of people with Down syndrome

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 14, 2006, Pages 3772-3776

  Kim, Nam Doo ^a   Yoon, Jeonghyeok ^a   Kim, Jung Ho ^b   Lee, Jung Tae ^b   Chon, Yong Sog ^b   Hwang, Mi Kyung ^b   Ha, Ilho ^c   Song, Woo Joo ^c  

^a Research Center IDRTech Inc   (South Korea)

^b Hanwha Corporation   (South Korea)

^c Inje University   (South Korea)

Author keywords

Down syndrome; DYRK1A; Inhibitor; Learning and memory deficits; Pharmacophore

Indexed keywords

DYRK1A INHIBITOR; DYRK1A PROTEIN; PROTEIN; PROTEIN INHIBITOR; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DOWN SYNDROME; DRUG ISOLATION; DRUG STRUCTURE; IN VITRO STUDY; LEARNING DISORDER; MEMORY DISORDER; MENTAL DEFICIENCY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

AMINO ACIDS; ANIMALS; BINDING SITES; DISEASE MODELS, ANIMAL; DOWN SYNDROME; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; LEARNING DISORDERS; MEMORY DISORDERS; MICE; MOLECULAR STRUCTURE; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES;

EID: 33746795070     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.04.042     Document Type: Article

References (28)

1. Jacobs P.A., Baikie A.G., Court Brown W.M., and Strong J.A. Lancet 1 (1959) 710
2. Lejeune J., Gautier M., and Turpin R. C. R. Hebd. Seances Acad. Sci. 248 (1959) 1721
3. Patterson D. Sci. Am. 257 (1987) 52
4. Korenberg J.R., Chen X.N., Schipper R., Sun Z., Gonsky R., Gerwehr S., Carpenter N., Daumer C., Dignan P., Disteche C., Graham J.M., Hugdins L., McGillivray B., Miyazaki K., Ogasawara N., park J.P., pagon R., Peuschel S., Sack F., Say B., Schuffenhauer S., Soukup S., and Yamanaka Y. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4997
5. Pulsifer M.B. J. Int. Neuropsychol. Soc. 2 (1996) 159
6. Lott I.T., Osann K., Doran E., and Nelson L. Arch. Neurol. 59 (2002) 1133
7. Bianchetti A., Trabucchi M., and Cipriani G. Int. J. Geriatr. Psychiatry 18 (2003) 657
8. Lobaugh N.J., Karaskov V., Rombough V., Rovet J., Bryson S., Greenbaum R., Haslam R.H., and Koren G. Arch. Pediatr. Adolesc. Med. 155 (2001) 442
9. Guimera J., Casas C., Pucharcos C., Solans A., Domenech A., Planas A.M., Ashley J., Lovett M., Estivill X., and Pritchard M.A. Hum. Mol. Genet. 5 (1996) 1305
10. Kentrup H., Becker W., Heukelbach J., Wilmes A., Schurmann A., Huppertz C., Kainulainen H., and Joost H.G. J. Biol. Chem. 271 (1996) 3488
11. Shindoh N., Kudoh J., Maeda H., Yamaki A., Minoshima S., Shimizu Y., and Shimizu N. Biochem. Biophys. Res. Commun. 225 (1996) 92
12. Song W.J., Sternberg L.R., Kasten-Sportes C., Keuren M.L., Chung S.H., Slack A.C., Miller D.E., Glover T.W., Chiang P.W., Lou L., and Kurnit D.M. Genomics 38 (1996) 331
13. Smith D.J., Stevens M.E., Sudanagunta S.P., Bronson R.T., Makhinson M., Watabe A.M., O'Dell T.J., Fung J., Weier H.U., Cheng J.F., and Rubin E.M. Nat. Genet. 16 (1997) 28
14. Altafaj X., Dierssen M., Baamonde C., Marti E., Visa J., Guimera J., Oset M., Gonzalez J.R., Florez J., Fillat C., and Estivill X. Hum. Mol. Genet. 10 (2001) 1915
15. Ahn, K. J.; Chung, H. K.; Choi, H. S.; Ryoo, S. R.; Kim, Y. J.; Goo, J. S.; Choi, S. Y.; Han, J. S.; Ha, I.; Song, W.-J. Neurobiol. Dis. 2006, in press.
16. Mutant Dyrk1A(Y321F) overexpressing transgenic mice did not show the learning and memory deficit (manuscript in preparation).
17. Bertrand J.A., Thieffine S., Vulpetti A., Cristiani C., Valsasina B., Knapp S., Kalisz H.M., and Flocco M. J. Mol. Biol. 333 (2003) 393
18. Himpel S., Panzer P., Eirmbter K., Czajkowska H., Sayed M., Packman L.C., Blundell T., Kentrup H., Grotzinger J., Joost H.G., and Becker W. Biochem. J. 359 (2001) 497
19. Insight 2000; Accelrys, Inc., San Diego, CA 2001, .
20. TM, will be published elsewhere in the near future.
21. 32P-ATP, followed by liquid scintillation counting. The kinase assay was performed by incubating DYRKtide (50 μM) with Dyrk1A (0.2 μM) in a kinase buffer containing 5 μM ATP at RT for 20 min. The inhibition of the kinase reaction was measured by quantifying the amount of the remaining ATP in the reaction using kinase-glo luminescent reagent as described (Promega, V-6711).
22. Bain J., McLauchlan H., Elliott M., and Cohen P. Biochem. J. 371 (2003) 199
23. Lochhead P.A., Sibbet G., Morrice N., and Cleghon V. Cell 121 (2005) 925
24. 4 and protease inhibitor. After the addition of protein A beads (PIERCE, cat. no. 20333), the captured Dyrk1A-antibody complex was subjected to 8% SDS-PAGE and Western analysis for phospho-Tyr detection by the PY99 antibody (Santa Cruz, cat. no. sc-7020).
25. Upstate's commercial KinaseProfiler™ Selectivity Testing Service was used to study the specificities of compounds 9 and 10.
26. Becker W., and Joost H.G. Prog. Nucleic Acid Res. Mol. Biol. 62 (1999) 1
27. Davies S.P., Reddy H., Caivano M., and Cohen P. Biochem. J. 351 (2000) 95
28. Vieth M., Higgs R.E., Robertson D.H., Shapiro M., Gragg E.A., and Hemmerle G.H. Biochim. Biophy. Acta 1697 (2004) 243